Novartis

May 22, 2015November 9, 2015

Novartis Presents Results for Compound That Improves COPD Lung Function at ATS 2015

COPD, News

Novartis recently announced the results of the EXPEDITION trial, a phase III study that is evaluating the efficacy of QVA149 (indacaterol/glycopyrronium) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). ... Read more

March 11, 2015March 11, 2015

Zykadia by Novartis Recommended For EU Approval To Treat ALK+ NSCLC Patients Previously Treated With Crizotinib

Lung Cancer, News

Zykadia from Novartis was recommended for EU approval to address treatment for adult patients suffering from anapestic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), also known as ALK+NSCLC, which has been treated previously with crizotinib. If ... Read more

February 9, 2015November 9, 2015

Novartis’ Ultibro Breezhaler For COPD Now Available In Quebec

COPD, News

After being recently launched in the UK, the Ultibro® Breezhaler® has been added to the list of medications recognized by the Régie de l’assurance malady du Québec (RAMQ) as a “Médicament d’exception,” and is ... Read more

January 16, 2015November 6, 2015

Ciprofloxacin Dry Powder for Inhalation Tested in Bronchiectasis

Bronchiectasis, News

Bayer and Novartis, two leading pharmaceutical companies, are developing ciprofloxacin dry powder for inhalation (DPI, brand name Cipro Inhale) to treat non-cystic fibrosis bronchiectasis. A phase 2 clinical trial, “Evaluation ... Read more

January 9, 2015November 11, 2015

Novartis Submits New Drug Applications For Two New COPD Therapies

COPD, News

Novartis submitted two New Drug Applications (NDAs) for QVA149 and NVA237 for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) to the U.S. Food and Drug Administration (FDA). ... Read more

January 9, 2015November 11, 2015

Novartis Reveals Two COPD Drugs’ Positive Phase III Results and NDA Submission

COPD, News

Novartis recently announced robust findings from a pivotal Phase III clinical study for QVA149 (indacaterol/glycopyrronium bromide) and NVA237 (glycopyrronium bromide), meant to support these pipeline medications’ New Drug Applications with the ... Read more

September 30, 2014November 6, 2015

FDA Includes Heart and Brain Problems to Asthma Drug Xolair’s Potential Risks

Asthma, News

The U.S. Food and Drug Administration (FDA) recently reviewed its drug safety recommendations, suggesting an increase in the risk of heart and blood problems as a result of the use of Xolair ... Read more

September 9, 2014November 11, 2015

Novartis Claims Once-Daily Ultibro Breezhaler Beats Seretide in Reducing COPD Flare-ups

COPD, News

For the first time, Novartis presented recent results showing a once-a-day Ultibro® Breezhaler® reduces disease exacerbations, i.e. an increase in disease severity, and improves lung function in patients with moderate-to-severe ... Read more